Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851
Go back to Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851| Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) | Delayed: 1.92 +0.03 (1.59%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.89 | 52 Week High | $19.62 | |||
| Open | $1.89 | 52 Week Low | $7.65 | |||
| Day High | $2.03 | P/E | N/A | |||
| Day Low | $1.88 | EPS | $-0.22 | |||
| Volume | 2,994,445 | |||||
